Program
Anti-Folate Receptor Alpha Antibody-drug Conjugate ABBV-901
In AbbVie’s pipeline, fr-alpha
. Its studies are mostly in Ovarian Neoplasms, led by AbbVie.
Furthest: phase 1, since Dec 2, 20251 company-led study, 1 open or runningNext primary completion: Dec 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 11 open or running | phase 1since Dec 2, 2025 | Dec 2, 2025 | Dec 2028phase 1 · NCT07278336 |
- Named in AbbVie’s own pipeline as
ABBV-901
, phase 1, as of Jul 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 2, 2025First study: phase 1 study in Ovarian NeoplasmsFirst studyNCT07278336 · 285 planned · United States, Australia, France and more
Ahead
- Dec 2028Primary completion: phase 1 study in Ovarian NeoplasmsNCT07278336
TargetBeta
“fr-alpha”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting folate receptor alpha (FRa; FolRa; FOLR1) ”NCIt, by rule
Other programs on FOLR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| mirvetuximab soravtansinerule | AbbVie | phase 3 | 15 |
| rinatabart sesutecanrule | Genmab | phase 3 | 9 |
| torvutatug samrotecan | AstraZeneca | phase 3 | 5 |
| sofetabart mipitecan | Eli Lilly | phase 3 | 2 |
| opugotamig olatansine | AbbVie | phase 2 | 2 |
| Anti-FRa/Anti-CD3 Bispecific TCE NTB-928rule | teneoseven-inc | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07278336Ovarian Neoplasms · United States, Australia, France and more | 1 | Recruiting | Dec 2028 | 285 |
How it is read
Names in the registry
- “ABBV-901”, 1 entry
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.